Regencell Bioscience
As the final bells rang on the 2025 trading year, investors in Regencell Bioscience (NASDAQ: RGC) were met with a sobering reality check. The Hong Kong-based biotech firm, which has enjoyed a meteoric and often volatile rise over the past twelve months, saw its stock slide 8.3% on December
Biotech
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the industry has closed the year with a powerful rally, fueled by a dovish shift from the Federal Reserve and
Biotech
As the final trading days of 2025 wind down, the biotechnology sector finds itself caught in a paradoxical "bifurcated" squeeze. While the broader indices have touched record highs this year, a sharp wave of year-end tax-loss harvesting has sent many mid-cap and commercial-stage biotech firms into a tailspin.
S&P 500
As the curtain closes on 2025, the financial landscape presents a tale of two markets. While the S&P 500 (NYSEARCA: SPY) hovers near the historic 7,000-point milestone, fueled by a 19% year-to-date rally and a resilient "soft landing" for the U.S. economy, a stark
Biotech
As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three quarters of the year, the rare-disease specialist has encountered a late-year slump, retreating from its 52-week
Dynavax
In a blockbuster conclusion to the 2025 trading year, Dynavax Technologies (NASDAQ:DVAX) saw its stock price skyrocket by nearly 40% in premarket trading this morning, December 24, 2025. The surge follows the official announcement that global pharmaceutical giant Sanofi (NASDAQ:SNY) has entered into a definitive agreement to acquire
CTOR
CRANFORD, NJ — As the 2025 calendar year draws to a close, Citius Oncology, Inc. (Nasdaq: CTOR) has reached a pivotal juncture in its corporate evolution. Following the release of its SEC 10-K filing for the fiscal year ended September 30, 2025, the company has officially shed its "development-stage"
Onshoring
The global financial landscape is witnessing a seismic shift as international corporations increasingly abandon their home markets to "onshore" in the United States. At the heart of this movement is Massachusetts, which has transformed from a regional innovation hub into a global "landing pad" for companies
Abivax
As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results and a staggering 1,400% year-to-date rally, the French biotechnology firm has been officially crowned the most
West Pharmaceutical Services
As the pharmaceutical industry undergoes its most significant transformation in decades, the spotlight often falls on the blockbuster drugs themselves—the weight-loss miracles and the life-saving biologics. However, a quieter, equally vital revolution is happening in the delivery systems that bring these treatments to patients. West Pharmaceutical Services (NYSE: WST)
Biotech
After a tumultuous first half of 2025 that saw the pharmaceutical and biotechnology sectors languish under a cloud of regulatory dread, the industry is ending the year on a surprisingly high note. The primary driver of this turnaround has been the resolution of long-standing pricing uncertainties, as most major drugmakers
Biotech
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts by surprise. After years of trading in the shadow of high interest rates and regulatory uncertainty, the industry